

Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies

Joni V. Lindbohm, MD, PhD;^{1,2} Nina Mars, MD, PhD;³ Keenan A. Walker, PhD;⁴ Prof. Archana Singh-Manoux, PhD;^{1,5} Prof. Gill Livingston, MD, PhD;^{6,7} Prof. Eric J. Brunner, PhD;¹ Pyry N. Sipilä, MD, PhD;² Prof. Kalle Saksela, MD, PhD;⁸ Jane E. Ferrie, PhD;^{1,9} Prof. Ruth Lovering, PhD;¹⁰ Stephen A. Williams, MD, PhD;¹¹ Prof. Aroon D. Hingorani, MD, PhD;^{12,13,14} Prof. Rebecca F. Gottesman, MD, PhD;⁴ Prof. Henrik Zetterberg, MD, PhD;^{15,16,17} Prof. Mika Kivimäki, PhD, FMedSci^{1,2}

¹ Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, UK

² Clinicum, Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland

³ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

⁴ Department of Neurology, The Johns Hopkins University, Baltimore, MD, USA.

⁵ Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Paris, France

⁶ Division of Psychiatry, University College London, London, UK

⁷ Camden and Islington Foundation Trust, London, UK

⁸ Department of Virology, University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland

⁹ Bristol Medical School (PHS), University of Bristol, Bristol, UK

¹⁰ Functional Gene Annotation, Institute of Cardiovascular Science, University College London, London, UK

¹¹ SomaLogic, Inc. Boulder, CO, USA

¹² Institute of Cardiovascular Science, University College London, London, UK.

¹³ University College London, British Heart Foundation Research Accelerator, London, UK.

¹⁴ Health Data Research UK, London, UK.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹⁵ Department of Neurodegenerative Disease and UK Dementia Research Institute, University College London, UK

¹⁶ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden

¹⁷ Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

Correspondence to Joni Lindbohm, Clincum, Department of Public Health, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland; E-mail address: joni.lindbohm@helsinki.fi; Telephone: +358 9 1911 Fax: +358 9 191 27 600

Word count: 3446/4000

Abstract

The role of circulating proteins in Alzheimer's disease and related dementias is unknown. Using a follow-up of two decades, 4953 plasma proteins, and discovery (Whitehall II) and replication cohort (ARIC), we examined plasma proteins associated with cognitive decline rate and dementia. After replication and adjustment for known dementia risk factors, fifteen proteins were associated with cognitive decline rate and dementia. None of these were amyloid, tau, or neurofilament-related proteins. Currently approved medications can target five of the proteins. The results support systemic pathogenesis of dementias, may aid in early diagnosis, and suggest potential targets for drug development.

Introduction

Alzheimer's disease and related dementias pose an increasing challenge with considerable costs to the individual and to health and social care services.¹ Until recently, amyloid beta and tau proteins have dominated pathophysiological models of dementia aetiology.² However, numerous prevention and treatment trials targeting these biomarkers have failed.^{3,4} In addition, longitudinal studies suggest that most cognitively normal amyloid-positive people never develop clinical dementia.⁵ Given this and the high prevalence of mixed types of dementia in the general population, there is a need to expand research on early biomarkers for dementia beyond amyloid and tau.

Causes of dementia are increasingly thought to be systemic.^{6,7} Recent development of scalable platforms allows simultaneous assessment thousands of circulating proteins.^{8,9} These have the potential to identify drivers of dementia, and move the field beyond amyloid and tau. For several reasons, circulating proteins are promising targets for biomarker and drug discovery. Proteins are regulators and effectors of biological processes and also imprints of the effects of genes, the environment, age, current co-morbidities, behaviours, and medications, all of which may affect dementia development.¹⁰ Proteins are also highly druggable as they can be targeted by monoclonal antibodies, small molecule drugs, or proteolysis-targeting chimaeras.¹¹⁻¹⁴ Indeed, of all currently approved medications, approximately 96% target proteins.¹¹ Animal studies also support a causal role of circulating plasma proteins in neurodegeneration. Plasma from young mice, via injection or through parabiosis (joining two animals so they share blood circulation) has been shown to restore memory and stimulate synaptic plasticity in the aged mouse hippocampus.¹⁵⁻¹⁷ In humans, multiple circulating proteins have been linked with dementia, but the studies to date have been mainly cross-sectional, based on small samples, or lacked replication.¹⁸

In this report from two large cohort studies, the British Whitehall II and the US Atherosclerosis Risk in Communities (ARIC) study, we used SomaScan technology to examine 4953 plasma proteins, including 22 related to amyloid, tau, or neurofilaments, as risk factors for

cognitive decline and dementia. To determine what role proteins play in the early stages of neurodegeneration when dementia may still be preventable, we assessed plasma proteins in late middle age and followed subsequent cognitive decline and dementia over two decades. Thus, our study design explicitly takes into consideration the long preclinical phase of dementia.

Results

In the random sample of 2274 participants in the Whitehall II discovery cohort, mean age was 56.1 (SD 5.9) and 1653 (73.0%) were men (**Table 1 and Figure 1**). During a mean follow-up of 20.4 years, 106 individuals developed dementia (36 were Alzheimer's, 19 vascular, and 51 mixed or other dementias). **Figure 2, part A** shows that those who developed dementia had steeper cognitive decline slopes than participants who remained dementia-free. After FDR correction, 246 of the 4953 proteins were associated with increased rate of cognitive decline (**Figure 2, part B**). None of the amyloid-, tau-, or neurofilament-related proteins were associated with accelerated cognitive decline after FDR correction (**Supplementary Table 1 and Supplementary Table 2**).

Of the 246 proteins, 21 were also associated with incident dementia in the Whitehall II study (**Figure 2, part C**). Thus, replication analyses in ARIC were based on 21 proteins. In this cohort, 1942 of the 11 395 participants developed dementia during a mean follow-up of 17.4 years. Fifteen of the 21 proteins associated with cognitive decline and dementia in the Whitehall II study were also associated with dementia in the ARIC cohort (**Figure 2, part D**) with the hazard ratios ranging between 1.08 and 1.64 in age, sex, and ethnicity/race adjusted analyses.

In additional analyses based on the Whitehall data, the 15 protein-dementia associations changed little after further adjustment for age, sex, ethnicity, SBP, antihypertensive medication, BMI, alcohol consumption, smoking, diabetes, socio-economic, and *APOE* status (**Supplementary Figures 1 and 2**) and taking into account competing risk of death (**Supplementary Figure 3**). A cognitive domain specific analysis suggested that phonemic fluency

and executive functioning mostly drove the associations with increased rate of cognitive decline (**Supplementary Tables 3-7**). There were no strong correlations between the 15 proteins (all correlations $\leq |0.53|$, **Supplementary Figure 4**).

The 15 proteins were mostly expressed in tissues other than the brain (**Figure 3 and Supplementary Table 8**). Of the proteins, 14 were secreted and one was a cell membrane protein. All of them were related to one or more biological systems that are relevant to dementia aetiology: dysfunction of the immune system and blood-brain barrier (BBB), vascular pathology, and central insulin resistance (**Table 1**). For five proteins, a medication that can influence the protein's function (NPS-PLA2, CDCP1, and IGFBP-7) or reduce its levels (N-terminal pro-BNP, and OPG) is available. All these medications have passed phase III trials and are used to treat diabetes, inflammatory- or cardiovascular diseases (**Supplementary Table 9**).

Discussion

This study identified 15 plasma proteins that were associated with increased rate of cognitive decline and increased 20-year risk of dementia in the British Whitehall II study. Of these 14 were secreted (N-terminal pro-BNP, CDCP1, MIC-1, CRDL1, RNAS6, SAP3, HE4, TIMP-4, IGFBP-7, OPG, SVEP1, TREM2, NPS-PLA2, MARCKSL1), and one was a cell membrane protein (SIGLEC-7), all mostly expressed outside central nervous system. The associations with dementia were replicated in an independent US cohort study, ARIC; were robust to adjustments for known dementia risk factors, such as hypertension, smoking, diabetes, and *APOE* status; and were not explained by competing risk of death. Of the 15 proteins, 5 (CDCP1, NPS-PLA2, IGFBP-7, N-terminal pro-BNP, and OPG) are modifiable using existing medications indicated for conditions other than dementias. To our knowledge, this is the largest proteome-wide study with replicated

results on the long-term associations between plasma proteins, cognitive decline and risk of dementia.

Our database search on protein expression profiles found that genes encoding the 15 proteins are mainly expressed in tissues other than the brain. This suggests that the elevated circulating protein levels in individuals at increased dementia risk are unlikely to represent markers of neurodegeneration resulting from proteins leaking from damaged cells in the central nervous system. In contrast, the expression profiles are consistent with the hypothesis that the identified proteins relate to systemic processes that increase dementia risk.

Of the 15 protein-dementia associations, seven (SVEP1, HE4, CDCP1, SIGLEC-7, MARCKSL1, CRDL1, and RNAS6) are novel, six (SAP3, NPS-PLA2, IGFBP-7, MIC-1, TIMP-4, OPG) have been previously reported in case-control studies¹⁹⁻²⁶ and two (TREM2, N-terminal pro-BNP) in prospective cohort studies,²⁷⁻²⁹ all showing the same direction as in this study.

Eleven of the proteins (six novel and five previously identified) are associated with immune response (**Figures 4A and B**). Of these, NPS-PLA2, TREM2, MIC-1, OPG and TIMP-4,^{21, 24, 25, 27, 30-35} have been considered to increase dementia risk due to involvement in activation, adhesion, survival promotion, and infiltration of neutrophils and macrophages. We identified two additional proteins, SVEP1 and MARCKSL1, which may also act in these processes.^{36,37} SVEP1 can also activate the complement system, which, if prolonged, can be detrimental to endothelial cells.³⁸ Leakage of complement through damaged endothelium into the CNS, in turn, can cause the synapse loss in the hippocampus observed in dementia.³⁹ This is supported by a recent consortium-based case-control study that showed an association between complement related sCR1, factor B, and factor H and Alzheimer's disease.⁴⁰ The elevated levels of SVEP1 among asymptomatic individuals who developed dementia in the present study suggests that SVEP1 might play a role in abnormal complement activation that predisposes to dementia.⁴¹

CDCP1 is a further identified immune-system related protein. It is a ligand for CD6 on T-cells, which upregulates T-cell activation and infiltration, and increases synthesis of pro-inflammatory cytokines.⁴² According to multiple sclerosis mouse models, anti-CD-6 antibodies ameliorate, and CD6 and CDCP1 knock out protects from encephalomyelitis⁴² suggesting that higher levels of CDCP1 might predispose to central inflammation. SIGLEC-7 is an inhibitory receptor in NK-cells that recognizes “self” antigens and prevents NK cell attacks on healthy cells.⁴³ In uncontrolled inflammation, SIGLEC-7 is cleaved and released into the plasma.^{44, 45} Thus elevated plasma SIGLEC-7 may reflect NK-cell activation towards healthy tissues, a potential risk factor for BBB dysfunction and CNS damage.

HE4 and RNAS6, in turn, are involved in antimicrobial responses to pathogens. HE4 is a broad-spectrum protease inhibitor⁴⁶ protecting against proteolytic microbial virulence. RNAS6 belongs to antimicrobial proteins and peptides (AMPs) that are secreted to blood in response to pathogens^{47, 48} after infection has breached epithelium.^{47, 48} The influence of direct antimicrobial responses in dementia pathogenesis is supported by the antimicrobial protection hypothesis,⁴⁹ which suggests that amyloid β can act as an AMP and protect against pathogens in the CNS.⁴⁹ However, prolonged activation of this process leads to amyloid deposition.

In combination, these findings support the hypotheses that inflammation and pathogens can cause chronic hyper-activation of innate and adaptive immunity, which then contributes to the development of Alzheimer’s disease and vascular dementia.^{41, 49, 50}

Proteins SAP3, TIMP-4, MIC-1, and OPG have been found to be related to BBB degeneration (**Figure 4C**). Elevated SAP3 levels have been observed in the cerebrospinal fluid of Alzheimer’s and Parkinson’s disease patients^{19, 51} and are linked with pericyte degeneration in the retina,⁵² leading to retinopathy as a complication of diabetes.⁵³ As pericyte degeneration is also observed in BBB breakdown, both mechanisms could play a role in development of dementia. TIMP-4 regulates the activity of multiple metalloproteinases⁵⁴ that can predispose to BBB

degeneration,⁶ but it is unclear whether elevated TIMP-4 levels are indicators of BBB-degrading processes or damage to the BBB by fibrinogen accumulation. Increased MIC-1 and OPG are also thought to reflect endothelial dysfunction.⁵⁵⁻⁵⁷ CDCP1 is linked with tight junction degeneration⁵⁸⁻⁶⁰ and HE4 is a broad spectrum proteinase inhibitor,⁴⁶ similar to TIMP-4. MARCKSL1 participates in maintaining endothelia integrity and when cleaved, its elevated plasma levels may reflect endothelial damage.^{61, 62} SVEP1 can cleave E-selectin that induces apoptosis and dysfunction in endothelium and binds to integrin $\alpha 9 \beta 1$ linked with basement membrane dysfunction.⁶³

Damaged BBB passes circulating TREM2, MARCKSL1, CRDL1, SAP3 and NPS-PLA2 into the CNS contributing to reduced neuronal plasticity, activation of microglia, disruptions in lipid metabolism, and increased neuroinflammation, amyloid and tau accumulation, and neurodegeneration.^{7, 30, 31, 64-67} These findings support the hypothesis that BBB degradation with subsequent passage of toxins and proteins into CNS may play an important aetiological role in dementia.⁶ We are not aware of previous studies showing that circulating TREM2 already in middle adulthood is associated with increased dementia risk at older ages.

Seven previously identified and three novel proteins are likely to play a role in vascular pathologies (**Figure 4D**). TIMP-4, SAP3, NPS-PLA2, OPG, and MIC-1 have been linked to dementia and atherosclerosis, remodelling of atherosclerotic plaques, platelet aggregation and thrombosis, and leukocyte invasion into atherosclerotic plaques.^{54, 55, 57, 68-73} N-terminal pro-BNP is known to be elevated in response to atrial and ventricular overload⁷⁴ and in plasma and the CNS it can inhibit the activity of neprilysin, an enzyme that reduces amyloid β levels.⁷⁵ Elevated N-terminal pro-BNP levels are also linked with increased risk of vascular and Alzheimer's dementia.^{28, 29, 76, 77} Of the proteins not previously linked to dementia, SVEP1 is known to promote thrombosis,^{78, 79} and HE4 and CRDL1 participate in angiogenesis in response to ischemia⁸⁰⁻⁸² and might contribute to the abnormal angiogenesis observed in vascular and Alzheimer's dementia.^{6, 83}

These results provide a variety of mechanisms that could predispose to cerebrovascular dysfunction in dementias.

IGFBP-7 is a protein with high affinity to insulin, and lower affinity to growth factors IGF-1 and IGF-2.^{84, 85} It is related to reduced central blood flow by restricting free insulin⁸⁵ in blood which leads to decreased insulin-NO-mediated vasodilation that can predispose to ischemia (**Figures 4D and E**). IGFBP-7 also prevents insulin from binding to its receptor.⁸⁵ All these properties are linked to reduced insulin responsiveness indicating that IGFBP-7 may be one of the factors behind central insulin resistance linked with dementia,⁸⁶ a hypothesis supported by a case-control study showing elevated IGFBP-7 levels in the urine of Alzheimer's dementia patients.²⁰

Our findings are of potential importance to drug repurposing and research on preventive medication for dementia. Varespladib inhibits the arachidonic acid pathway in inflammation by inhibiting NPS-PLA2 activity, and may counteract inflammation that predisposes to dementia.⁸⁷ Similarly, itolizumab prevents CDCP1 from binding to CD6, leading to downregulation in T-cell mediated inflammation.⁸⁸ Randomized control trials on intranasal insulin have shown promising results in improving amyloid and tau profiles and cognition in individuals with cognitive decline or Alzheimer's dementia.⁸⁶ Whether more tailored medication that targets IGFBP-7 can be used to ameliorate central insulin resistance should be investigated. Glucose lowering and statin medications linked with reduced inflammation in diabetes are also associated with reduced OPG levels;^{56, 89, 90} further research should determine whether OPG plays a role in the disease process leading to dementia. Currently available antihypertensive medications can be used to reduce plasma N-terminal pro-BNP levels,⁷⁴ but whether a drug that directly targets N-terminal pro-BNP is beneficial for cognitive decline and dementia needs to be tested.

This study's strengths include its large sample size, simultaneous assessment of thousands of proteins, replication of main findings in an independent study population, and the early baseline that allowed assessment of proteins two decades before dementia diagnosis when no

changes in plasma amyloid or tau markers were present. Only three dementia cases occurred within the first 10 years of follow-up suggesting low risk of reverse causation. However, observational evidence cannot determine causal associations and therefore our findings should be considered as hypothesis generating. Other limitations include the lack of repeated protein measurements to assess whether changes in protein levels over time are associated with dementia risk; the use of semi-quantitative protein data that cannot determine clinically useful concentrations; and the lack of information on dementia subtypes based on brain imaging or cerebrospinal fluid biomarkers.

In conclusion, using large-scale testing of plasma proteins as long-term risk factors for cognitive decline and dementia, we have provided strong support for the hypothesis that early systemic processes may drive development of dementias. The protein-dementia associations identified and replicated were plausible, involving innate and adaptive immunity, BBB dysfunction, vascular pathology, and central insulin resistance that all can contribute to amyloid and tau deposition, or pathologies that characterise vascular dementia. Our findings point to proteins that may be potential biomarkers and drug targets for dementia, the first crucial step to discover disease-modifying medications that can expand the field beyond amyloid and tau.

Methods

Study design and participants

We used the Whitehall II study as our discovery cohort and the ARIC study as the replication cohort (**Figure 1**). In 1985-1988, all civil servants aged 35 to 55 years based in 20 departments in London, UK, were invited to participate in the Whitehall II cohort study, and 73% (n=10 308) agreed.⁹¹ Blood samples for proteomic analyses were collected from a random subsample of 2274 dementia-free individuals in 1997-99.⁹² Cognitive performance measurements were conducted at this and four subsequent clinical examinations in 2002-2004, 2007-2009, 2012-13, and 2015-2016. Follow-up started from 1997-99 and ended at death, dementia, or October 2019.

ARIC⁹³ is a community-based cohort study of 15,792 participants from four US communities: Washington County, Maryland; Forsyth County, North Carolina; North-western suburbs of Minneapolis, Minnesota; and Jackson, Mississippi. Participants were aged 44 to 66 years at baseline in 1987-1989. Blood samples for protein analysis were drawn in 1993-1995 and analysed for 11 395 individuals free of dementia. Incident dementia cases were identified during the 1996-1998, 2011-2013 and 2016-2017 clinical examinations and using data from informant interviews, hospital records and death certificates.

Assessment of plasma proteins

In Whitehall II and ARIC, proteins were analysed using the SomaScan version 4 assay. Earlier studies describe performance of the SomaScan assay and the modified aptamer-binding in detail.⁹⁴⁻
⁹⁶ In brief, the SomaScan Assay is a multiplexed aptamer-based immunoassay that uses a library of DNA molecules designed to identify specific proteins. The aptamers bind to the target protein in plasma samples and the unspecific fast off rate proteins are washed away. The slow off rate proteins are labelled with biotin and the aptamer-protein complexes incubated in a buffer containing unlabelled polyanionic competitor. This step is analogous to the effect of adding a second antibody to increase specificity in a conventional immunoassay. The aptamer-protein complexes are then recaptured with streptavidin and again washed to remove non-specific aptamer-protein complexes. The aptamers are then released from the proteins, hybridized to complementary sequences on a DNA microarray chip, and quantified by fluorescence. The fluorescence intensity reflects the concentration of each protein. Median intra- and inter-assay coefficients of variation are ~5% and assay sensitivity is comparable to that of typical immunoassays, with a median lower limit of detection in the femtomolar range.⁹⁵ Specificity of the modified aptamer reagents is good and has been tested in several ways.⁹²

Cognitive testing

The Whitehall II cognitive test battery covered four domains: executive function, memory, phonemic-, and semantic fluency (**Supplementary Methods**). Executive function was assessed with the Alice Heim 4-I test, memory with a 20-word free recall test and phonemic and semantic fluency with word and animal name recall tests.^{97,98} To minimize measurement error inherent in individual tests, we created a global cognitive score by standardizing each test domain measured in follow-up visits to the baseline score, and then standardizing the summary scores from each phase to the baseline summary score.⁹⁹ This allowed construction of individual slopes of decline in cognition.

Dementia follow-up

Whitehall II study participants are linked to the National Health Services (NHS) Hospital Episode Statistics (HES) database, and the British National mortality register using individual NHS identification numbers for linkage.¹⁰⁰ The NHS provides nearly complete comprehensive health care coverage for all individuals legally resident in the UK. Incident dementia was defined by the WHO International Classification of Diseases, version 10 (ICD-10) codes F00, F01, F03, G30, and G31 and ICD-9 codes 290.0-290.4, 331.0-331.2, 331.82, and 331.9. We also conducted informant interviews and checked participants' medications at each screening for dementia-related medication. Sensitivity and specificity of dementia assessment based on the HES data is 0.78 and 0.92.¹⁰¹

In ARIC, incident dementias were primarily identified using comprehensive clinical and neuropsychological examinations and informant interviews from visits 5 (2011-2013) and 6 (2016-2017).^{102, 103} Using all the data available, suspected cases were adjudicated by a committee of clinicians. In between visits, participants were contacted annually via telephone and administered a brief cognitive screener, and their caregivers, a questionnaire. This information, supplemented by

surveillance of dementia-related hospital discharge and death certificate codes, was used to estimate the dementia onset date.

Measurement of baseline covariates

In the Whitehall II study, standard self-administered questionnaires provided data on age, sex, ethnicity, socioeconomic status, education, alcohol consumption, and smoking. Experienced clinical nurses measured BMI and systolic blood pressure (SBP) and took blood samples for lipid and glucose measurements.⁹¹ Using DNA extracted from whole blood, a standard PCR assay determined *APOE* genotype using the salting out method.^{104, 105} Two independent observers read the genotype blind and any discrepancies were resolved by repeating the PCR analysis. In ARIC, baseline covariates included age, sex, and a combined race-study centre variable.

Statistical analysis

We used Spearman correlation to test protein-protein correlations. In the Whitehall II study, individual cognitive measurements were plotted and group means derived with local linear smooth plots for descriptive purposes.¹⁰⁶ The proteins were transformed to normal distribution by inverse rank-based normal transformation. We used age and sex adjusted linear regression to study associations between each protein and the cognitive decline slopes, derived with mixed-effects linear regression, and formed a Manhattan plot based on $-\log_{10}(\text{p-values})$. The assumptions of linear regression were assessed by plotting the residuals in residuals versus fitted, normal Q-Q, scale-location, and residual versus leverage plots.¹⁰⁶ We used false discovery rate correction (FDR) of 5% to select proteins for further analyses; this translated to p-value cut-off of 0.002. The proteins that survived FDR correction were analysed in age, sex, and ethnicity adjusted Cox regression models¹⁰⁷ with incident dementia as the outcome and p-value=0.05 as the cut-off for statistical significance. All the p-values were two-sided. The proportionality assumption in all Cox models

was assessed with Schoenfeld residuals and with log-log plots.¹⁰⁷ In sensitivity analyses Cox regression was adjusted for age, sex, ethnicity, SBP, antihypertensive medication, BMI, alcohol consumption, smoking, diabetes, socio-economic, and *APOE* status. We also studied the effect of competing risk of death with the Fine and Gray model.¹⁰⁸ To examine reproducibility, proteins that were robustly associated with cognitive decline and dementia in the Whitehall II study were also analysed in the ARIC study. These Cox models with dementia as outcome were adjusted for age, sex and race-study centre.

We searched the Genotype-Tissue Expression (GTEx),¹⁰⁹ Human Protein Atlas,^{110, 111} Database for Annotation, Visualization and Integrated Discovery (DAVID),^{112, 113} Uniprot,¹¹⁴ and ChEMBL¹¹⁵ databases to characterize protein expression profiles, their cellular localization, and drugs that can target them. We used statistical software R (3.6.0) and Stata (version 16.1 MP; Stata Corp, College Station, TX, USA) for all analyses.

Contributors

MK, AH, AS-M, GL, EJB, NM and JVL generated the hypothesis and designed the study. JVL, NM, KS and HZ provided initial mechanistic interpretations. JVL, with MK, wrote the first draft of the report. JVL did the primary analyses, with support from NM, and performed literature searches. KW ran the replication analysis. All authors interpreted the data and critically commented and reviewed the report. JVL had full access to pseudonymised data from the Whitehall II study and KW had full access to the ARIC data.

Declaration of interests

In this is an academic–industry partnership project academic collaborators generated the hypothesis and study design and SomaLogic, Inc. provided expertise in plasma proteins and funded SomaScan assays. SAW is employed by SomaLogic, Inc., which has a commercial interest in the results. ASM reports grants from the National Institute on Aging, NIH. RCL reports grants from Alzheimer's Research UK. RG was as previous Associate Editor for the journal Neurology. HZ reports grants from the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research, the Alzheimer Drug Discovery Foundation, USA, and the UK Dementia Research Institute. Additionally, HZ reports that he has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. EJB reports grants from British Heart Foundation and UK Research and Innovation. MK reports grants from UK Medical Research Council, US National Institute on Aging, Academy of Finland, Helsinki Institute of Life Science, NordForsk, and the Finnish Work Environment Fund, during the conduct of the study.

Data sharing

Data, protocols, and other metadata of the Whitehall II and ARIC studies are available to the scientific community. Please refer to the data sharing policies of these studies. Pre-existing data access policies for Whitehall II and ARIC studies specify that research data requests can be submitted to each steering committee; these will be promptly reviewed for confidentiality or intellectual property restrictions and will not unreasonably be refused. Individual-level patient or protein data may further be restricted by consent, confidentiality, or privacy laws/considerations. These policies apply to both clinical and proteomic data.

Code availability

This manuscript did not include any custom code and used only pre-existing statistical packages.

Acknowledgments

The study was supported by the UK Medical Research Council (S011676, K013351, R024227), the National Institute on Aging (National Institutes of Health; R01AG056477 and R01AG062553), the British Heart Foundation (32334), the Academy of Finland (311492), NordForsk (75021), and SomaLogic, Inc. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from: Median gene-level TPM by tissue dataset from the GTEx Portal on 9/2/2020. JVL was supported by Academy of Finland (311492) and Helsinki Institute of Life Science (H970) and AS-M and AGT were supported by NordForsk (75021, the Nordic Research Programme on Health and Welfare), during the conduct of the study. ASM is supported by the National Institute on Aging, NIH (R01AG062553;R01AG056477). RCL was supported by Alzheimer's Research UK grant ARUK-NAS2017A-1. HZ is a Wallenberg Scholar supported by grants from the Swedish

Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation, USA (201809-2016862), and the UK Dementia Research Institute at UCL. EJB was supported by British Heart Foundation (RG/16/11/32334) and UK Research and Innovation (ES/T014377/1). MK was supported by UK Medical Research Council (MR/S011676, MR/R024227), US National Institute on Aging (R01AG062553, R01AG056477), Academy of Finland (311492), Helsinki Institute of Life Science (H970), NordForsk (75021), and the Finnish Work Environment Fund (190424). The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641, R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Neurocognitive data is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD). Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. This study was also supported by contracts K23 AG064122 (Dr. Walker) and K24 AG052573 (Dr. Gottesman) from NIA. UCL and Johns Hopkins University have signed a collaboration agreement with SomaLogic, Inc to conduct SOMAscan of Whitehall and ARIC stored samples at no charge in exchange for the rights to analyse linked Whitehall and ARIC phenotype data.

References

1. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* **18**, 88-106 (2019).
2. Jack, C. R., Jr *et al.* Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol.* **12**, 207-216 (2013).
3. Gauthier, S. *et al.* Why has therapy development for dementia failed in the last two decades? *Alzheimers Dement.* **12**, 60-64 (2016).
4. Knopman, D. S. Lowering of Amyloid-Beta by β -Secretase Inhibitors - Some Informative Failures. *N. Engl. J. Med.* **380**, 1476-1478 (2019).
5. Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. *Alzheimers Dement.* **14**, 981-988 (2018).
6. Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R. & Zlokovic, B. V. Blood-Brain Barrier: From Physiology to Disease and Back. *Physiol. Rev.* **99**, 21-78 (2019).
7. Shi, Y. & Holtzman, D. M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. *Nat. Rev. Immunol.* **18**, 759-772 (2018).
8. Assarsson, E. *et al.* Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PLoS One* **9**, e95192 (2014).
9. Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* **5**, e15004 (2010).
10. Emilsson, V. *et al.* Co-regulatory networks of human serum proteins link genetics to disease. *Science* **361**, 769-773 (2018).
11. Santos, R. *et al.* A comprehensive map of molecular drug targets. *Nat. Rev. Drug Discov.* **16**, 19-34 (2017).
12. Chessum, N. E. A. *et al.* Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). *J. Med. Chem.* **61**, 918-933 (2018).
13. Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimer's disease drug development pipeline: 2018. *Alzheimers Dement. (N. Y)* **4**, 195-214 (2018).
14. Scudellari, M. Protein-slaying drugs could be the next blockbuster therapies. *Nature* **567**, 298-300 (2019).
15. Katsimpardi, L. *et al.* Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. *Science* **344**, 630-634 (2014).
16. Middeldorp, J. *et al.* Preclinical Assessment of Young Blood Plasma for Alzheimer Disease. *JAMA Neurol.* **73**, 1325-1333 (2016).

17. Sha, S. J. *et al.* Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial. *JAMA Neurol.* **76**, 35-40 (2019).
18. Hampel, H. *et al.* Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat. Rev. Neurol.* **14**, 639-652 (2018).
19. Heywood, W. E. *et al.* Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Mol. Neurodegener* **10**, 64-015-0059-y (2015).
20. Yao, F. *et al.* Urine-Based Biomarkers for Alzheimer's Disease Identified Through Coupling Computational and Experimental Methods. *J. Alzheimers Dis.* **65**, 421-431 (2018).
21. Chai, Y. L. *et al.* Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. *Medicine (Baltimore)* **95**, e4566 (2016).
22. Jiang, J., Wen, W. & Sachdev, P. S. Macrophage inhibitory cytokine-1/growth differentiation factor 15 as a marker of cognitive ageing and dementia. *Curr. Opin. Psychiatry.* **29**, 181-186 (2016).
23. Qin, W. *et al.* Elevated plasma angiogenesis factors in Alzheimer's disease. *J. Alzheimers Dis.* **45**, 245-252 (2015).
24. Emanuele, E. *et al.* Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. *Int. J. Mol. Med.* **13**, 849-853 (2004).
25. Jefferson, A. L. *et al.* Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. *Neurology* **68**, 1032-1038 (2007).
26. Moses, G. S. *et al.* Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. *J. Neuroinflammation* **3**, 28-2094-3-28 (2006).
27. Ohara, T. *et al.* Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study. *Ann. Neurol.* **85**, 47-58 (2019).
28. Kerola, T. *et al.* B-type natriuretic peptide as a predictor of declining cognitive function and dementia--a cohort study of an elderly general population with a 5-year follow-up. *Ann. Med.* **42**, 207-215 (2010).
29. Tynkkynen, J. *et al.* NT-proBNP and the risk of dementia: a prospective cohort study with 14 years of follow-up. *J. Alzheimers Dis.* **44**, 1007-1013 (2015).
30. Murphy, A. *et al.* Induction of protein kinase C substrates, Myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP), by amyloid beta-protein in mouse BV-2 microglial cells. *Neurosci. Lett.* **347**, 9-12 (2003).
31. Sunohara, J. R., Ridgway, N. D., Cook, H. W. & Byers, D. M. Regulation of MARCKS and MARCKS-related protein expression in BV-2 microglial cells in response to lipopolysaccharide. *J. Neurochem.* **78**, 664-672 (2001).

32. Farooqui, A. A. & Horrocks, L. A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. *Neuroscientist* **7**, 232-245 (2001).
33. Fuchs, T. *et al.* Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. *Aging Cell*. **12**, 882-889 (2013).
34. Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. *Cell. Metab.* **28**, 353-368 (2018).
35. Whelan, C. D. *et al.* Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. *Acta Neuropathol. Commun.* **7**, 169-019-0795-2 (2019).
36. Gilgés, D. *et al.* Polydom: a secreted protein with pentraxin, complement control protein, epidermal growth factor and von Willebrand factor A domains. *Biochem. J.* **352 Pt 1**, 49-59 (2000).
37. Van Itallie, C. M. *et al.* MARCKS-related protein regulates cytoskeletal organization at cell-cell and cell-substrate contacts in epithelial cells. *J. Cell. Sci.* **131**, jcs210237. doi: 10.1242/jcs.210237 (2018).
38. Huber-Lang, M., Lambris, J. D. & Ward, P. A. Innate immune responses to trauma. *Nat. Immunol.* **19**, 327-341 (2018).
39. Ennerfelt, H. E. & Lukens, J. R. The role of innate immunity in Alzheimer's disease. *Immunol. Rev.* (2020).
40. Morgan, A. R. *et al.* Inflammatory biomarkers in Alzheimer's disease plasma. *Alzheimers Dement.* **15**, 776-787 (2019).
41. Akiyama, H. *et al.* Inflammation and Alzheimer's disease. *Neurobiol. Aging* **21**, 383-421 (2000).
42. Enyindah-Asonye, G. *et al.* CD318 is a ligand for CD6. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E6912-E6921 (2017).
43. Fong, J. J. *et al.* Siglec-7 engagement by GBS \hat{I}^2 -protein suppresses pyroptotic cell death of natural killer cells. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 10410-10415 (2018).
44. Varchetta, S. *et al.* Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. *Retrovirology* **10**, 154-4690-10-154 (2013).
45. Varchetta, S. *et al.* Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. *Gut* **65**, 1998-2006 (2016).
46. LeBleu, V. S. *et al.* Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. *Nat. Med.* **19**, 227-231 (2013).
47. Becknell, B. *et al.* Ribonucleases 6 and 7 have antimicrobial function in the human and murine urinary tract. *Kidney Int.* **87**, 151-161 (2015).

48. Lu, L. *et al.* Human Antimicrobial RNases Inhibit Intracellular Bacterial Growth and Induce Autophagy in Mycobacteria-Infected Macrophages. *Front. Immunol.* **10**, 1500 (2019).
49. Moir, R. D., Lathe, R. & Tanzi, R. E. The antimicrobial protection hypothesis of Alzheimer's disease. *Alzheimers Dement.* **14**, 1602-1614 (2018).
50. Readhead, B. *et al.* Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* **99**, 64-82.e7 (2018).
51. Sjödin, S. *et al.* Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. *Alzheimers Res. Ther.* **11**, 82-019-0533-9 (2019).
52. Masson, E., Wiernsperger, N., Lagarde, M. & El Bawab, S. Involvement of gangliosides in glucosamine-induced proliferation decrease of retinal pericytes. *Glycobiology* **15**, 585-591 (2005).
53. Caseiro, A. *et al.* Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. *Transl. Res.* **163**, 188-199 (2014).
54. Brew, K., Dinakarandian, D. & Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. *Biochim. Biophys. Acta* **1477**, 267-283 (2000).
55. Lind, L. *et al.* Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. *Eur. Heart J.* **30**, 2346-2353 (2009).
56. Kadoglou, N. P. *et al.* Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. *J. Vasc. Surg.* **51**, 114-121 (2010).
57. Pérez de Ciriza, C., Lawrie, A. & Varo, N. Osteoprotegerin in Cardiometabolic Disorders. *Int. J. Endocrinol.* **2015**, 564934 (2015).
58. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. *Cell* **69**, 11-25 (1992).
59. Windham, T. C. *et al.* Src activation regulates anoikis in human colon tumor cell lines. *Oncogene* **21**, 7797-7807 (2002).
60. Thomas, S. M. & Brugge, J. S. Cellular functions regulated by Src family kinases. *Annu. Rev. Cell Dev. Biol.* **13**, 513-609 (1997).
61. Braun, T., McIlhinney, R. A. & Vergères, G. Myristoylation-dependent N-terminal cleavage of the myristoylated alanine-rich C kinase substrate (MARCKS) by cellular extracts. *Biochimie* **82**, 705-715 (2000).
62. Guo, Y. *et al.* Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. *Mol. Cell. Proteomics* **6**, 689-696 (2007).

63. Schwanzer-Pfeiffer, D., Rossmannith, E., Schildberger, A. & Falkenhagen, D. Characterization of SVEP1, KIAA, and SRPX2 in an in vitro cell culture model of endotoxemia. *Cell. Immunol.* **263**, 65-70 (2010).
64. Blanco-Suarez, E., Liu, T. F., Kopelevich, A. & Allen, N. J. Astrocyte-Secreted Chordin-like 1 Drives Synapse Maturation and Limits Plasticity by Increasing Synaptic GluA2 AMPA Receptors. *Neuron* **100**, 1116-1132.e13 (2018).
65. Sun, M. *et al.* Presynaptic contributions of chordin to hippocampal plasticity and spatial learning. *J. Neurosci.* **27**, 7740-7750 (2007).
66. Gruber, A., Mancek, M., Wagner, H., Kirschning, C. J. & Jerala, R. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. *J. Biol. Chem.* **279**, 28475-28482 (2004).
67. Villanueva, E. B., Little, J. P., Lambeau, G. & Klegeris, A. Secreted phospholipase A(2) group IIA is a neurotoxin released by stimulated human glial cells. *Mol. Cell. Neurosci.* **49**, 430-438 (2012).
68. Ibeas, E., Fuentes, L., Martín, R., Hernández, M. & Nieto, M. L. Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis. *Cardiovasc. Res.* **81**, 54-63 (2009).
69. Hazen, S. L., Ford, D. A. & Gross, R. W. Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate. *J. Biol. Chem.* **266**, 5629-5633 (1991).
70. Yanai, H., Yoshida, H., Tomono, Y., Tada, N. & Chiba, H. The Possible Contribution of a General Glycosphingolipid Transporter, GM2 Activator Protein, to Atherosclerosis. (2006).
71. Melendez-Zajgla, J., Del Pozo, L., Ceballos, G. & Maldonado, V. Tissue inhibitor of metalloproteinases-4. The road less traveled. *Mol. Cancer.* **7**, 85-4598-7-85 (2008).
72. Santos-Martínez, M. J., Medina, C., Jurasz, P. & Radomski, M. W. Role of metalloproteinases in platelet function. *Thromb. Res.* **121**, 535-542 (2008).
73. Tummalapalli, C. M., Heath, B. J. & Tyagi, S. C. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. *J. Cell. Biochem.* **80**, 512-521 (2001).
74. Singh, J. S. S. *et al.* Sacubitril/valsartan: beyond natriuretic peptides. *Heart* **103**, 1569-1577 (2017).
75. Hu, W. T. *et al.* Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology* **79**, 897-905 (2012).
76. Hilal, S. *et al.* Markers of cardiac dysfunction in cognitive impairment and dementia. *Medicine (Baltimore)* **94**, e297 (2015).
77. Kondziella, D., Göthlin, M., Fu, M., Zetterberg, H. & Wallin, A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. *Neuroreport* **20**, 825-827 (2009).

78. Dhanesha, N. *et al.* Targeting myeloid-cell specific integrin $\alpha 9\beta 1$ inhibits arterial thrombosis in mice. *Blood* **135**, 857-861 (2020).
79. Dhanesha, N. *et al.* Targeting Myeloid-Specific Integrin $\alpha 9\beta 1$ Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. *Circ. Res.* **126**, 1779-1794 (2020).
80. Sakuta, H. *et al.* Vetroptin: a BMP-4 antagonist expressed in a double-gradient pattern in the retina. *Science* **293**, 111-115 (2001).
81. Kane, R., Godson, C. & O'Brien, C. Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis. *Mol. Vis.* **14**, 1138-1148 (2008).
82. James, N. E. *et al.* The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes. *Sci. Rep.* **10**, 8558-020-65353-x (2020).
83. Iadecola, C. The pathobiology of vascular dementia. *Neuron* **80**, 844-866 (2013).
84. Evdokimova, V. *et al.* IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. *Sci. Signal.* **5**, ra92 (2012).
85. Yamanaka, Y., Wilson, E. M., Rosenfeld, R. G. & Oh, Y. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. *J. Biol. Chem.* **272**, 30729-30734 (1997).
86. Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. *Lancet Neurol.* (2020).
87. Nicholls, S. J. *et al.* Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *JAMA* **311**, 252-262 (2014).
88. Dogra, S., Uprety, S. & Suresh, S. H. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. *Expert Opin. Biol. Ther.* **17**, 395-402 (2017).
89. Nybo, M. *et al.* Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. *Basic Clin. Pharmacol. Toxicol.* **109**, 481-485 (2011).
90. Esteghamati, A., Afarideh, M., Feyzi, S., Noshad, S. & Nakhjavani, M. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. *Diabetes Metab. Syndr.* **9**, 258-265 (2015).
91. Marmot, M. G. *et al.* Health inequalities among British civil servants: the Whitehall II study. *Lancet* **337**, 1387-1393 (1991).
92. Williams, S. A. *et al.* Plasma protein patterns as comprehensive indicators of health. *Nat. Med.* **25**, 1851-1857 (2019).

93. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am. J. Epidemiol.* **129**, 687-702 (1989).
94. Kim, C. H. *et al.* Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. *Sci. Rep.* **8**, 8382-018-26640-w (2018).
95. Candia, J. *et al.* Assessment of Variability in the SOMAscan Assay. *Sci. Rep.* **7**, 14248-017-14755-5 (2017).
96. Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* **5**, e15004 (2010).
97. Heim, A. AH 4 group test of general intelligence. *NFER-Nelson Publishing Company* (1970).
98. Borkowski, J., Benton, A. & Spreen, O. Word fluency and brain damage. *Neuropsychologia* **5**, 135-40 (1967).
99. Wilson, R. S., Leurgans, S. E., Boyle, P. A., Schneider, J. A. & Bennett, D. A. Neurodegenerative basis of age-related cognitive decline. *Neurology* **75**, 1070-1078 (2010).
100. Kivimaki, M. *et al.* Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records. *Epidemiology* **28**, 735-739 (2017).
101. Sommerlad, A. *et al.* Accuracy of general hospital dementia diagnoses in England: Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. *Alzheimers Dement.* **14**, 933-943 (2018).
102. Walker, K. A. *et al.* Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. *JAMA* **322**, 535-545 (2019).
103. Gottesman, R. F. *et al.* Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. *JAMA Neurol.* **74**, 1246-1254 (2017).
104. Bolla, M. K., Wood, N. & Humphries, S. E. Rapid determination of apolipoprotein E genotype using a heteroduplex generator. *J. Lipid Res.* **40**, 2340-2345 (1999).
105. Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res.* **16**, 1215 (1988).
106. Gareth, J., Witten, D., Hastie, T. & Tibshirani, R. in *An Introduction to Statistical Learning: With Applications in R.* (Springer Publishing Company, Incorporated., 2014).
107. Cox, D. R. Regression Models and Life-Tables. *Journal of the Royal Statistical Society. Series B (Methodological)* **34**, 187-220 (1972).
108. Fine JP, G. R. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *Journal of the American Statistical Association.*, 496-509 (1999).
109. <https://gtexportal.org/home/datasets>.

110. <http://www.proteinatlas.org>.

111. Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).

112. Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* **37**, 1-13 (2009).

113. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44-57 (2009).

114. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* **47**, D506-D515 (2019).

115. Gaulton, A. *et al.* The ChEMBL database in 2017. *Nucleic Acids Res.* **45**, D945-D954 (2017).

Tables and Figures

Table 1. Whitehall and ARIC participant characteristics at the time of blood collection for protein measurement. Values are displayed as means (SD) for continuous variables, frequency (column percentages) for categorical variables, and interquartile range (IQR) for follow-up time.

Characteristic, n (%) or mean (SD)	Whitehall II N=2274	ARIC N=11 395
Demographic variables		
Age, mean (SD)	56.1 (5.9)	60.2 (5.7)
Men, No. (%)	1653 (73.0)	5190 (45.6)
White, No. (%)	2089 (92.3)	8991 (78.9)
Education, No. (%)		
Less than high school	522 (31.1)	2311 (20.3)
High school/vocational	427 (25.4)	4813 (42.3)
College/graduate/ professional	731 (43.5)	4255 (37.4)
Apolipoprotein E ε4 alleles, No. (%)		
0	1432 (73.4)	7678 (67.4)
1	469 (24.1)	3358 (29.5)
2	49 (2.5)	359 (3.2)
Physiological and lab variables, mean (SD)		
Body mass index, kg/m ²	26.6 (4.1)	28.5 (5.6)
Total cholesterol, mg/dl	6.0 (1.0)	5.4 (1.0)
Cardiovascular risk factors, No. (%)		
Hypertension	286 (12.6)	4686 (41.3)
Diabetes mellitus	13 (0.6)	1806 (15.9)
Cigarette smoking, current	204 (9.1)	2042 (18.0)
Mean follow-up time (SD)	20.4 (3.2)	17.7 (6.1)
Median follow-up time (IQR)	21.5 (21.0, 22.1)	20.0 (14.1, 22.4)



Figure 1. Flowchart of the study design.

Figure 2. Summary of the three steps in protein analysis.

Protein name	HGNC gene name	Whitehall II		ARIC	
		HR (95% CIs)	p-value	HR (95% CIs)	p-value
Associations replicated					
N-terminal pro-BNP	NPPB	1.52 (1.24 to 1.88)	<0.001	1.08 (1.03 to 1.13)	0.003
CDCP1	CDCP1	1.42 (1.16 to 1.73)	<0.001	1.26 (1.17 to 1.37)	<0.001
MIC-1	GDF15	1.31 (1.04 to 1.65)	0.02	1.64 (1.49 to 1.82)	<0.001
CRDL1	CHRDL1	1.30 (1.06 to 1.59)	0.01	1.20 (1.01 to 1.42)	0.04
RNAS6	RNASE6	1.30 (1.07 to 1.57)	0.01	1.23 (1.11 to 1.37)	<0.001
SAP3	GM3A	1.29 (1.06 to 1.57)	0.01	1.32 (1.12 to 1.55)	0.001
HE4	WFDC2	1.29 (1.04 to 1.60)	0.02	1.44 (1.28 to 1.62)	<0.001
TIMP-4	TIMP4	1.29 (1.05 to 1.59)	0.02	1.12 (1.01 to 1.26)	0.04
IGFBP-7	IGFBP7	1.27 (1.05 to 1.54)	0.01	1.43 (1.18 to 1.72)	<0.001
OPG	TNFRSF11B	1.26 (1.02 to 1.56)	0.03	1.34 (1.20 to 1.50)	<0.001
SIGLEC-7	SIGLEC7	1.25 (1.03 to 1.52)	0.02	1.24 (1.06 to 1.45)	0.01
SVEP1	SVEP1	1.24 (1.02 to 1.51)	0.03	1.39 (1.23 to 1.58)	<0.001
TREM2	TREM2	1.24 (1.01 to 1.51)	0.04	1.13 (1.04 to 1.23)	0.003
NPS-PLA2	PLA2G2A	1.24 (1.01 to 1.51)	0.04	1.13 (1.03 to 1.25)	0.01
MARCKSL1	MARCKSL1	1.22 (1.01 to 1.48)	0.04	1.11 (1.01 to 1.22)	0.04
Associations not replicated					
SPONDIN-1	SPON1	1.34 (1.09 to 1.63)	0.01	1.18 (1.00 to 1.40)	0.06
IGFBP-2	IGFBP2	1.28 (1.05 to 1.57)	0.02	1.06 (0.99 to 1.13)	0.09
NEUROPEPTIDE W	NPW	1.25 (1.02 to 1.53)	0.03	1.03 (1.00 to 1.07)	0.09
ST4S6	CHST15	1.24 (1.02 to 1.50)	0.03	0.96 (0.78 to 1.18)	0.72
TPPP2	TPPP2	0.82 (0.68 to 1.00)	0.05	1.04 (0.93 to 1.17)	0.46
LEAP-1	HAMP	0.82 (0.67 to 0.99)	0.04	1.02 (0.97 to 1.06)	0.48

D) Of the 21 protein-dementia associations (2C), 15 were replicated in ARIC. No amyloid, tau, or neurofilament related protein was associated with cognitive decline and dementia

Figure 3. Expression profile in transcripts per million (TPM) of the genes coding the 15 proteins associated with cognitive decline and dementia that survived multivariate adjustment, competing risks, and replication.





Table 2. Associations between the proteins and dementia related pathologies, existing evidence of these associations, and current medications that can influence protein function or level

Protein	Immune system	BBB* dysfunction	Vascular pathology	Central insulin resistance	Previous studies	Medications (indication)
N-terminal pro-BNP	-	-	1	-	Prospective cohort ^{27,28,76,77}	Antihypertensive medications (hypertension) ⁷⁴
CDCP1	1	1	-	-	None	Itolizumab ⁸⁸ (psoriasis)
MIC-1	1	1	1	-	Case control ^{22,23}	-
CRDL1	-	-	1	-	None	-
RNAS6	1	-	-	-	None	-
SAP3	-	1	1	-	Case-control ¹⁹	-
HE4	1	1	1	-	None	-
TIMP-4	1	1	1	-	Case-control ²³	-
IGFBP-7	-	-	1	1	Case-control ²⁰	Intranasal insulin, metformin, and GLP-1 receptor agonists ⁸⁶ (Alzheimer's disease, diabetes)
OPG	1	1	1	-	Case-control ²⁵	Atorvastatin, metformin, glitazones ^{56,89,90} (atherosclerotic cardiovascular diseases, diabetes)
SIGLEC-7	1	-	-	-	None	-
SVEP1	1	1	1	-	None	-
TREM2	1	-	-	-	Prospective cohort ²⁷	-
NPS-PLA2	1	-	1	-	Case-control ²⁷	Varespladib and Varespladib Methyl ⁸⁷ (cardiovascular and inflammatory diseases)
MARCKSL1	1	1	-	-	None	-
Total	11	8	10	1		

*BBB = blood brain barrier


Figure 4. Dementia-related pathologies for the 15 proteins associated with cognitive decline rate and increased dementia incidence

A) Innate immunity




B) Adaptive immunity

Capillary



C) Blood brain barrier breakdown



D) Atherosclerosis and thrombosis

1) **TIMP-4** is associated with remodelling in labile atherosclerotic plaques, promotes thrombosis formation, and is apoptotic to damaged myocytes that is linked to arteriosclerosis

2) **OPG** is associated with macrophage invasion, smooth cell hyperplasia and fibrosis in atherosclerosis

3) **NPS-PLA2** promotes macrophage mediated inflammation in atherosclerotic plaques

4) **SAP3** transports glycosphingolipid to atherosclerotic plaques that relate to macrophages transfer to foam cells and causes smooth muscle cell hypoplasia

5) **SVEP1** activates neutrophils that promote thrombosis

6) **MIC-1** is associated with atherosclerosis but it is unclear whether it is a marker or a factor in its development


7) **HE4 and TIMP-4** increases protease activity and may increase fibrin(ogen) accumulation in the perivascular space

8) Atherosclerosis and small vessel disease reduce cerebral blood flow which is further reduced by **IGFBP-7** via lower insulin availability and subsequent decrease in NO-mediated vasodilation

9) **HE4 and CRDL1** increase in response to ischemia leading to abnormal angiogenesis and endothelial disruption

10) **N-terminal pro-BNP** is a marker of atrial and ventricular overload that is associated with endothelial dysfunction

11) Endothelial dysfunction, impairment of autoregulation, and dysfunction of neurovascular coupling, additionally mediated by oxidative stress and NO deficit further reduce cerebral blood flow resulting in hypo perfusion and tissue hypoxia. This leads to expression of adhesion molecules in endothelium and contributes to leukocyte infiltration, platelet adhesion, microvascular occlusion, and micro bleeds.



E) Central insulin resistance

1) IGFBP-7 restricts mainly free insulin and to some extent free IGF-1 and IGF-2 levels in blood and inhibits their binding to their receptors

2) Reduced insulin levels lead to decrease in NO-mediated vasodilation and subsequently decrease in cerebral perfusion

3) IGFBP-7 restricts insulin availability and inhibits insulin and IGF-1 binding in neurons' insulin receptor leading to apoptosis and reduced neurogenesis

4) IGFBP-7 reduces availability of IGF-1 to IGF-1 receptor leading to neurodystrophic effects, neuroinflammation amyloid accumulation, and tau phosphorylation


5) IGFBP-7 reduces IGF-2 availability to IGF-2 receptor leading to dysregulation of endocytosis, lysosomes, and apoptosis

6) IGFBP-7 limits insulin availability to insulin dependent glucose transporter GLUT4 expressed in areas, such as hypothalamus, with high glucose demand

7) IGFBP-7 limits insulin availability that leads to reduced oligodendrocyte proliferation, survival, differentiation, and myelination.

8) IGFBP-7 reduces insulin availability that increases inflammatory response, reduces glycogen storage, and reduces BBB glucose uptake in astrocytes

9) IGFBP-7 reduces insulin availability to microglia that leads to inflammatory response and subsequent amyloid and tau accumulation and neurodegeneration



Supplement

Supplementary Methods

Cognitive testing

The Whitehall II cognitive test battery covered four domains: executive function, memory, phonemic-, and semantic fluency. Executive function was assessed with the Alice Heim 4-I test, that comprises a series of 65 verbal and mathematical reasoning items of increasing difficulty.⁹⁷ It tests inductive reasoning, measuring the ability to identify patterns and infer principles and rules, and has time limit of 10 minutes. A 20-word free recall test assessed memory. Participants were presented a list of one or two syllable words at two-second intervals and were then asked to recall in writing as many of the words as possible in any order with two minutes to do so. In assessment of phonemic and semantic fluency⁹⁸ participants were asked to recall in writing as many words beginning with “s” (phonemic fluency) and as many animal names (semantic fluency) as they could. Time limit for this section was one minute per fluency area.

Based on these measures, we created a global cognitive score by first standardizing the distribution of each test domain measured in follow-up visits to the baseline score to create z-scores with mean 0 and SD 1. We then summed the domain specific scores at each phase and standardized the summary score to the baseline summary score; this approach minimizes measurement error inherent in individual tests.⁹⁹ After dementia diagnosis, participants were rarely able to complete the cognitive tests and for this reason, their global test score was set to -3SD at phase that followed dementia diagnosis. Based on the global scores we derived a cognitive decline slope for each participant and used this as the outcome.

Supplementary Table 1. Hazard ratios between SD increase in amyloid, tau, and neurofilament related protein levels and cognitive decline. None of these survived false discovery rate (FDR) correction of 5%.

Protein	Cognitive decline	
	Beta	FDR p-value
Amyloid, tau, and neurofilament related proteins		
Amyloid beta precursor like protein 1	0.02	0.65
Amyloid beta precursor like protein 2	0.03	0.35
Serum amyloid A1	0.05	0.19
Serum amyloid A2	0.05	0.13
Serum amyloid A4	0.02	0.56
Amyloid P component, serum	0.02	0.53
Amyloid beta precursor protein	0.01	0.67
Amyloid beta precursor protein binding family B member 1	0.03	0.35
Amyloid beta precursor protein binding family B member 2	0.05	0.12
Amyloid beta precursor protein binding family B member 3	0.02	0.63
Microtubule associated protein RP/EB family member 1	-0.01	0.75
Microtubule associated protein RP/EB family member 2	-0.01	0.77
Microtubule associated protein RP/EB family member 3	-0.02	0.63
Microtubule associated proteins 1 light chain 3 alpha	0.03	0.38
Microtubule associated proteins 1 light chain 3 beta	0.01	0.82
Microtubule associated protein tau	0.03	0.36
Regulator of microtubule dynamics protein 1	0.01	0.86
Regulator of microtubule dynamics protein 3	0.02	0.59
Janus kinase and microtubule-interacting protein 3	0.06	0.05
Microtubule affinity regulating kinase 3	0.01	0.92
Neurofilament light	0.01	0.69
Neurofilament heavy	0.04	0.20

Supplementary Table 2. Amyloid, tau, and neurofilament related protein functions, tissue expression, and Gene Ontology terms from UniProt database.

Uniprot ID	HGNC gene symbol	HGNC gene name	Function: UniProt Summary (abridged), GO annotations (selected)	Tissue specificity (UniProt)
O00213	APBB1	amyloid beta precursor protein binding family B member 1	<p>UniProt Summary: Transcription coregulator that can have both coactivator and corepressor functions. Adapter protein that forms a transcriptionally active complex with the gamma-secretase-derived amyloid precursor protein (APP) intracellular domain. Plays a central role in the response to DNA damage by translocating to the nucleus and inducing apoptosis. May act by specifically recognizing and binding histone H2AX phosphorylated on 'Tyr-142' (H2AXY142ph) at double-strand breaks, recruiting other pro-apoptosis factors such as MAPK8/JNK1. Required for histone H4 acetylation at double-strand breaks. Its ability to specifically bind modified histones and chromatin modifying enzymes such as KAT5/TIP60, probably explains its transcription activation activity. Functions in association with TSHZ3, SET and</p>	Highly expressed in brain; strongly reduced in post-mortem elderly subjects with Alzheimer disease.

			<p>HDAC factors as a transcriptional repressor, that inhibits the expression of CASP4. Associates with chromatin in a region surrounding the CASP4 transcriptional start site(s).</p> <p>GO annotations: histone binding, low-density lipoprotein particle receptor binding, protein binding (to APP), transcription factor binding, cellular response to DNA damage stimulus, negative regulation of transcription by RNA polymerase II, positive regulation of protein secretion (of amyloid-beta), positive regulation of transcription by RNA polymerase II, cytoplasm, nucleus.</p>	
Q92870	APBB2	amyloid-beta A4 precursor protein-binding family B member 2	<p>UniProt Summary: May modulate the internalization of amyloid-beta precursor protein.</p> <p>GO annotations: amyloid-beta binding, protein binding (to APP), transcription factor binding, regulation of transcription DNA-templated, synapse organization, cytoplasm, nucleus, synapse.</p>	Ubiquitous.
O95704	APBB3	amyloid beta precursor protein binding	<p>UniProt Summary: May modulate the internalization of amyloid-beta precursor</p>	Expressed in various tissues, highest expression in brain.

		family B member 3	protein. GO annotations: amyloid-beta binding, low-density lipoprotein particle receptor binding, protein binding (to APP), transcription factor binding, positive regulation of protein secretion (of amyloid-beta), regulation of transcription DNA-templated, nucleus, cytoplasm.	
P02743	APCS	amyloid P component, serum	UniProt Summary: Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin. GO annotations: complement component C1q complex binding, low-density lipoprotein particle binding, acute-phase response, classical pathway, complement activation, extracellular space.	Found in serum and urine.
P51693	APLP1	amyloid beta precursor like protein 1	UniProt Summary: May play a role in postsynaptic function. The C-terminal gamma-secretase processed fragment, ALID1, activates transcription activation through APBB1 (Fe65) binding (By similarity). Couples to JIP signal transduction through C-terminal binding. May interact with cellular G-	Expressed in the cerebral cortex where it is localized to the postsynaptic density (PSD).

			<p>protein signaling pathways. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I.</p> <p>GO annotations: adrenergic receptor binding, heparin binding, protein binding (to APP), cellular response to norepinephrine stimulus, extracellular matrix organization, forebrain development, perinuclear region of cytoplasm, plasma membrane.</p>	
Q06481	APLP2	amyloid beta precursor like protein 2	<p>UniProt Summary: May play a role in the regulation of hemostasis. The soluble form may have inhibitory properties towards coagulation factors. May interact with cellular G-protein signaling pathways. May bind to the DNA 5'-GTCACATG-3'(CDEI box). Inhibits trypsin, chymotrypsin, plasmin, factor XIA and plasma and glandular kallikrein. Modulates the Cu/Zn nitric oxide-catalyzed autodegradation of GPC1 heparan sulfate side chains in fibroblasts (By similarity).</p> <p>GO annotations: heparin binding, protein binding (to APP), serine-type endopeptidase</p>	Expressed in placenta, brain, heart, lung, liver, kidney and endothelial tissues.

			inhibitor activity, negative regulation of endopeptidase activity, platelet degranulation, nucleus, plasma membrane.	
P05067	APP	amyloid beta precursor protein	<p>UniProt Summary: Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 towards synapses. Involved in copper homeostasis/oxidative stress through copper ion reduction. Can regulate neurite</p>	<p>Expressed in the brain and in cerebrospinal fluid (at protein level) (PubMed:2649245). Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.</p>

			<p>outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress</p>	
--	--	--	--	--

			<p>and neurotoxicity. Also binds GPC1 in lipid rafts. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis. N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). GO annotations: apolipoprotein binding, growth factor receptor binding, integrin binding, serine-type endopeptidase inhibitor activity, astrocyte activation, cell adhesion, cellular response to amyloid-beta, microglial cell activation, negative regulation of low-density lipoprotein receptor activity, positive regulation of apoptotic process, positive regulation of NIK/NF-kappaB signaling, regulation of transcription by RNA polymerase II, cell-cell junction, cytoplasm, extracellular space, plasma membrane, nucleus.</p>	
--	--	--	--	--

Q5VZ66	JAKMIP 3	Janus kinase and microtubule interacting protein 3	UniProt Summary: none available. GO annotations: kinase binding, microtubule binding, Golgi apparatus.	Specifically expressed in the CNS and endocrine tissues. Also detected in other tissues including heart, testis and prostate.
Q9H492	MAP1LC 3A	microtubule associated protein 1 light chain 3 alpha	UniProt Summary: Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes). While LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation. Through its interaction with the reticulophagy receptor TEX264, participates in the remodeling of subdomains of the endoplasmic reticulum into autophagosomes upon nutrient stress, which then fuse with lysosomes for endoplasmic reticulum turnover. GO annotations: microtubule binding, phosphatidylethanolami ne binding, phospholipid binding, ubiquitin protein ligase binding, autophagosome assembly, autophagy of mitochondrion, cellular response to nitrogen starvation, autophagosome membrane, cytosol.	Most abundant in heart, brain, liver, skeletal muscle and testis but absent in thymus and peripheral blood leukocytes.

Q9GZQ8	MAP1LC 3B	microtubule associated protein 1 light chain 3 beta	<p>UniProt Summary: Ubiquitin-like modifier involved in formation of autophagosomal vacuoles (autophagosomes). Plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. While LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation. Promotes primary ciliogenesis by removing OFD1 from centriolar satellites via the autophagic pathway. Through its interaction with the reticulophagy receptor TEX264, participates in the remodeling of subdomains of the endoplasmic reticulum into autophagosomes upon nutrient stress, which then fuse with lysosomes for endoplasmic reticulum turnover.</p> <p>GO annotations: microtubule binding, protein binding (to APP), ubiquitin protein ligase binding,</p>	Most abundant in heart, brain, skeletal muscle and testis. Little expression observed in liver.
--------	--------------	---	---	---

			autophagosome assembly, autophagy of mitochondrion, cellular response to nitrogen starvation, autophagosome membrane, axoneme, cytosol, mitochondrion.	
Q15691	MAPRE1	microtubule associated protein RP/EB family member 1	UniProt Summary: Plus-end tracking protein (+TIP) that binds to the plus-end of microtubules and regulates the dynamics of the microtubule cytoskeleton. Promotes cytoplasmic microtubule nucleation and elongation. May be involved in spindle function by stabilizing microtubules and anchoring them at centrosomes. Also acts as a regulator of minus-end microtubule organization: interacts with the complex formed by AKAP9 and PDE4DIP, leading to recruit CAMSAP2 to the Golgi apparatus, thereby tethering non-centrosomal minus-end microtubules to the Golgi, an important step for polarized cell movement. Promotes elongation of CAMSAP2-decorated microtubule stretches on the minus-end of microtubules. Acts as a regulator of	Ubiquitously expressed.

			<p>autophagosome transport via interaction with CAMSAP2. May play a role in cell migration (By similarity).</p> <p>GO annotations: microtubule plus-end binding, protein kinase binding, cell migration, ciliary basal body-plasma membrane docking, protein localization to microtubule plus-end, regulation of microtubule polymerization or depolymerization, spindle assembly, cytosol, centrosome, focal adhesion, microtubule organizing center, microtubule plus-end, spindle midzone.</p>	
Q15555	MAPRE2	microtubule associated protein RP/EB family member 2	<p>UniProt Summary: May be involved in microtubule polymerization, and spindle function by stabilizing microtubules and anchoring them at centrosomes. May play a role in cell migration (By similarity).</p> <p>GO annotations: microtubule plus-end binding, positive regulation of focal adhesion disassembly, positive regulation of keratinocyte migration, protein localization to microtubule plus-end, regulation of microtubule</p>	Expressed in different tumor cell lines. Up-regulated in activated B- and T-lymphocytes.

			polymerization or depolymerization, cytoplasm, focal adhesion, microtubule organizing center, microtubule plus-end, spindle midzone.	
Q9UPY8	MAPRE3	microtubule associated protein RP/EB family member 3	<p>UniProt Summary: Plus-end tracking protein (+TIP) that binds to the plus-end of microtubules and regulates the dynamics of the microtubule cytoskeleton. Promotes microtubule growth. May be involved in spindle function by stabilizing microtubules and anchoring them at centrosomes. Also acts as a regulator of minus-end microtubule organization: interacts with the complex formed by AKAP9 and PDE4DIP, leading to recruit CAMSAP2 to the Golgi apparatus, thereby tethering non-centrosomal minus-end microtubules to the Golgi, an important step for polarized cell movement. Promotes elongation of CAMSAP2-decorated microtubule stretches on the minus-end of microtubules. May play a role in cell migration (By similarity).</p> <p>GO annotations: microtubule plus-end binding, protein binding (to tau) protein kinase binding, cell migration,</p>	Predominantly expressed in brain and muscle.

			<p>ciliary basal body-plasma membrane docking, protein localization to microtubule plus-end, regulation of microtubule polymerization or depolymerization, spindle assembly, cytosol, centrosome, focal adhesion, microtubule organizing center, microtubule plus-end, spindle midzone.</p>	
P10636	MAPT	microtubule associated protein tau	<p>UniProt Summary: Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. GO annotations: actin binding, apolipoprotein binding, dynactin binding, microtubule</p>	<p>Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.</p>

			<p>binding, protein binding (to APP), protein phosphatase 2A binding, protein kinase binding, axonal transport of mitochondrion, microglial cell activation, microtubule cytoskeleton organization, negative regulation of mitochondrial membrane potential, negative regulation of tubulin deacetylation, neuron projection development, regulation of autophagy, regulation of chromosome organization, regulation of microtubule polymerization or depolymerization, stress granule assembly, synapse organization, cytosol, extracellular region, microtubule cytoskeleton, mitochondrion, neurofibrillary tangle, neuron projection, nucleus, plasma membrane.</p>	
P27448	MARK3	microtubule affinity regulating kinase 3	<p>UniProt Summary: Serine/threonine-protein kinase. Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU. Phosphorylates CDC25C</p>	Ubiquitous.

			<p>on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus. Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1.</p> <p>GO annotations: protein binding (to APP), protein serine/threonine kinase activity, tau-protein kinase activity, MAPK cascade, microtubule cytoskeleton organization, negative regulation of hippo signaling, peptidyl-serine phosphorylation, cytosol, dendrite, plasma membrane.</p>	
P12036	NEFH	neurofilament heavy	<p>UniProt Summary: Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. NEFH has an important function in mature axons that is not subserved by the two</p>	Ubiquitous.


			<p>smaller NF proteins. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity). GO annotations: dynein complex binding, kinesin binding, protein binding (to APP), protein kinase binding, microtubule binding, structural constituent of cytoskeleton, axonogenesis, intermediate filament cytoskeleton organization, microtubule cytoskeleton organization, neurofilament bundle assembly, regulation of organelle transport along microtubule, axon, cytoskeleton, neurofibrillary tangle, neurofilament, postsynaptic density.</p>	
P07196	NEFL	neurofilament light	<p>UniProt Summary: Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity).</p>	Ubiquitous.

			<p>GO annotations: phospholipase binding, protein binding (to APP), protein-macromolecule adaptor activity, structural constituent of cytoskeleton, intermediate filament organization, microtubule cytoskeleton organization, negative regulation of neuron apoptotic process, neurofilament bundle assembly, neuron projection morphogenesis, regulation of NMDA receptor activity, retrograde axonal transport, cell projection, cytoskeleton, intermediate filament,</p>	
Q96DB5	RMDN1	regulator of microtubule dynamics 1	<p>UniProt Summary: none available. GO annotations: microtubule binding, attachment of mitotic spindle microtubules to kinetochore, mitotic spindle organization, cytoplasm, microtubule, mitotic spindle pole, spindle microtubule.</p>	Ubiquitous.


Q96TC7	RMDN3	regulator of microtubule dynamics 3	<p>UniProt Summary: Involved in cellular calcium homeostasis regulation. May participate in differentiation and apoptosis of keratinocytes. Overexpression induces apoptosis.</p> <p>GO annotations: microtubule binding, apoptotic process, cell differentiation, cellular calcium ion homeostasis, cytoskeleton, mitochondrion, mitotic spindle pole, nucleus, spindle microtubule.</p>	<p>Present at high level in epidermis and seminiferous epithelium: while basal cells in the epidermis and spermatogonia show no perceptible amount, keratinocytes of suprabasal layers and differentiating first-order spermatocytes up to spermatids exhibit high expression. In skeletal muscle, its presence is restricted to fibers of the fast twitch type. In surface epithelia containing ciliated cells, it is associated with the microtubular structures responsible for ciliary movement. Also present in specific structures of the central nervous system such as neurons of the hippocampal region, ganglion cells of the autonomic nervous system, and axons of the peripheral nervous system (at protein level). Widely expressed. {ECO:0000269 PubMed:15609043, ECO:0000269 PubMed:16820967}.</p>
PODJI8	SAA1	serum amyloid A1	<p>UniProt Summary: Major acute phase protein.</p> <p>GO annotations: G protein-coupled receptor binding, heparin binding, innate immune response, lymphocyte chemotaxis, negative regulation of inflammatory response, platelet activation, positive regulation of cell adhesion, positive regulation of cytokine production, receptor-mediated endocytosis,</p>	<p>Expressed by the liver; secreted in plasma (at protein level). {ECO:0000269 PubMed:12973732, ECO:0000269 PubMed:4816450, ECO:0000269 PubMed:7115671}.</p>

			cytoplasmic microtubule, extracellular region, high-density lipoprotein particle.	
PODJI9	SAA2	serum amyloid A2	UniProt Summary: Major acute phase reactant. GO annotations: acute-phase response, extracellular region, high-density lipoprotein particle.	Expressed by the liver; secreted in plasma. {ECO:0000269 PubMed:3183061}.
P35542	SAA4	serum amyloid A4, constitutive	UniProt Summary: Major acute phase reactant. GO annotations: acute-phase response, extracellular region, high-density lipoprotein particle.	Expressed by the liver; secreted in plasma.


Supplementary Figure 1. Age and sex adjusted results for the 15 proteins associated with both cognitive decline and dementia in the Whitehall II study.



Supplementary Figure 2. Age, sex, SBP, antihypertensive medication, smoking, diabetes, *APOE* genotype, BMI, alcohol consumption, and socioeconomic status adjusted results for the 15 proteins associated with both cognitive decline and dementia in the Whitehall II study.



Supplementary Figure 3. Age, sex, SBP, antihypertensive medication, smoking, diabetes, *APOE* genotype, BMI, alcohol consumption, and socioeconomic status adjusted results from competing risks (death) model for the 15 proteins associated with both cognitive decline and dementia in the Whitehall II study.



Supplementary Table 3. Associations between the cognitive decline slope and a SD increase in the 15 proteins that survived replication.

Protein	Beta (95% CIs)	p-value	FDR corrected p-value
N-terminal pro-BNP	0.12 (0.08 to 0.17)	3E-09	2E-06
CDCP1	0.16 (0.12 to 0.20)	4E-14	1E-10
MIC-1	0.18 (0.14 to 0.22)	1E-17	7E-14
CRDL1	0.09 (0.05 to 0.13)	4E-05	0.0031
RNAS6	0.07 (0.03 to 0.11)	0.0007	0.023
SAP3	0.08 (0.04 to 0.12)	9E-05	0.0059
HE4	0.12 (0.08 to 0.16)	5E-09	2E-06
TIMP-4	0.08 (0.04 to 0.13)	7E-05	0.0050
IGFBP-7	0.10 (0.06 to 0.14)	2E-06	0.00040
OPG	0.12 (0.08 to 0.16)	5E-09	2E-06
SIGLEC-7	0.10 (0.05 to 0.14)	6E-06	0.00084
SVEP1	0.13 (0.09 to 0.17)	2E-09	1E-06
TREM2	0.09 (0.05 to 0.13)	3E-05	0.0027
NPS-PLA2	0.07 (0.03 to 0.11)	0.0014	0.035
MARCKSL1	0.07 (0.03 to 0.11)	0.0006	0.021

Supplementary Table 4. Associations between the memory decline slope and a SD increase in the 15 proteins that survived replication.

Protein	Beta (95% CIs)	p-value
N-terminal pro-BNP	0.01 (-0.03 to 0.05)	0.73
CDCP1	0.04 (0.00 to 0.08)	0.05
MIC-1	0.04 (0.00 to 0.08)	0.064
CRDL1	0.03 (-0.01 to 0.07)	0.20
RNAS6	-0.01 (-0.05 to 0.03)	0.63
SAP3	-0.02 (-0.06 to 0.02)	0.36
HE4	0.00 (-0.04 to 0.04)	0.88
TIMP-4	0.02 (-0.02 to 0.06)	0.33
IGFBP-7	0.06 (0.02 to 0.10)	0.0052
OPG	0.03 (-0.01 to 0.07)	0.13
SIGLEC-7	0.06 (0.01 to 0.10)	0.0088
SVEP1	0.02 (-0.02 to 0.07)	0.25
TREM2	0.01 (-0.04 to 0.05)	0.79
NPS-PLA2	0.03 (-0.01 to 0.08)	0.11
MARCKSL1	0.02 (-0.02 to 0.06)	0.43

Supplementary Table 5. Associations between the phonemic fluency decline slope and a SD increase in the 15 proteins that survived replication.

Protein	Beta (95% CIs)	p-value
N-terminal pro-BNP	0.10 (0.06 to 0.14)	1E-06
CDCP1	0.08 (0.04 to 0.12)	8E-05
MIC-1	0.08 (0.04 to 0.12)	0.0003
CRDL1	0.04 (0.00 to 0.08)	0.046
RNAS6	0.03 (-0.02 to 0.07)	0.22
SAP3	0.04 (0.00 to 0.08)	0.058
HE4	0.05 (0.01 to 0.09)	0.013
TIMP-4	0.06 (0.02 to 0.10)	0.0053
IGFBP-7	0.07 (0.02 to 0.11)	0.002
OPG	0.05 (0.01 to 0.09)	0.021
SIGLEC-7	0.03 (-0.01 to 0.07)	0.13
SVEP1	0.09 (0.05 to 0.13)	2E-05
TREM2	0.06 (0.02 to 0.11)	0.0024
NPS-PLA2	0.02 (-0.02 to 0.06)	0.33
MARCKSL1	0.06 (0.02 to 0.10)	0.0069

Supplementary Table 6. Associations between the semantic fluency decline slope and a SD increase in the 15 proteins that survived replication.

Protein	Beta (95% CIs)	p-value
N-terminal pro-BNP	0.04 (0.00 to 0.08)	0.056
CDCP1	0.04 (0.00 to 0.08)	0.055
MIC-1	0.06 (0.01 to 0.10)	0.0083
CRDL1	0.03 (-0.01 to 0.07)	0.13
RNAS6	0.01 (-0.03 to 0.05)	0.60
SAP3	0.05 (0.01 to 0.09)	0.022
HE4	0.03 (-0.01 to 0.07)	0.12
TIMP-4	-0.01 (-0.05 to 0.04)	0.79
IGFBP-7	0.03 (-0.01 to 0.07)	0.20
OPG	0.04 (0.00 to 0.08)	0.068
SIGLEC-7	0.02 (-0.02 to 0.07)	0.26
SVEP1	0.04 (0.00 to 0.08)	0.083
TREM2	0.02 (-0.03 to 0.06)	0.47
NPS-PLA2	0.00 (-0.04 to 0.04)	0.90
MARCKSL1	0.03 (-0.01 to 0.07)	0.19

Supplementary Table 7. Associations between the executive function decline slope and SD increase in the 15 proteins that survived replication.

Protein	HR (95% CIs)	p-value
N-terminal pro-BNP	0.14 (0.10 to 0.18)	3E-11
CDCP1	0.17 (0.12 to 0.21)	3E-15
MIC-1	0.20 (0.16 to 0.24)	9E-21
CRDL1	0.08 (0.04 to 0.12)	8E-05
RNAS6	0.10 (0.06 to 0.14)	3E-06
SAP3	0.10 (0.06 to 0.14)	3E-06
HE4	0.15 (0.10 to 0.19)	5E-12
TIMP-4	0.11 (0.07 to 0.15)	3E-07
IGFBP-7	0.06 (0.02 to 0.10)	0.0054
OPG	0.14 (0.10 to 0.18)	3E-11
SIGLEC-7	0.07 (0.03 to 0.11)	0.0007
SVEP1	0.13 (0.09 to 0.17)	1E-09
TREM2	0.09 (0.05 to 0.13)	9E-06
NPS-PLA2	0.09 (0.05 to 0.13)	3E-05
MARCKSL1	0.09 (0.04 to 0.13)	5E-05

Supplementary Table 8. Protein expression levels in the brain tissue for 15 proteins that survived replication.

Protein	Expression in brain
N-terminal pro-BNP	Not known
CDCP1	Low
MIC-1	Not detected
CRDL1	Not known
RNAS6	Not detected
SAP3	High
HE4	Low
TIMP-4	Not known
IGFBP-7	Not known
OPG	Not known
SIGLEC-7	Not known
SVEP1	Low
TREM2	Medium
NPS-PLA2	Not detected
MARCKSL1	Medium

Supplementary Table 9. Drugs that can influence proteins associated with dementia, their potential mechanisms of action and current indications.

Protein	Medication	Action	Indications
CDCP1	Itolizumab	Prevents CDCP1 binding to CD6 and down regulates T cell activation and infiltration. It also reduces synthesis of pro-inflammatory cytokines reducing T cell infiltration at sites of inflammation.	Psoriasis
NPS-PLA2	Varespladib and Varespladib Methyl	Inhibits arachidonic acid pathway in inflammation by inhibiting NPS-PLA2 activity and subsequent leukocyte activation.	Atherosclerotic cardiovascular diseases, inflammatory diseases, snake venom antidote
IGFBP-7	Intranasal insulin, metformin and GLP-1 receptor agonists	Insulin nasal spray restores central insulin levels that may be down regulated by elevated IGFBP-7 levels. Metformin acts as insulin sensitizer and GLP-1 agonists stimulate insulin secretion.	Cognitive decline and Alzheimer's disease
N-terminal pro-BNP	Antihypertensive medications	Reduce N-terminal pro-BNP levels in circulation by reducing atrial and ventricular overload.	Hypertension
OPG	Atorvastatin, metformin, pioglitazone, rosiglitazone	Reduce OPG levels possibly by reducing inflammation and by stabilizing atherosclerotic plaques.	Atherosclerotic cardiovascular diseases, diabetes